Early Alzheimer's disease diagnosis and blood biomarkers: primary care physician attitudes, perceptions and barriers in the USA
This study highlights PCPs' engagement and interest in supporting AD diagnosis as well as their receptivity towards BBMs. PCPs are generally positive about integrating BBMs into their clinical practice. However, clarity on healthcare coverage and context of use is needed before adoption. Continued medical education on diagnosing AD as well as interpretation and communication of BBM test results will be beneficial for primary care involvement in AD diagnosis.
Authors
- Justine Coppinger (ORCID: https://orcid.org/0009-0000-4137-930X)
- Rosemary D. Laird
- Sutapa Ray (ORCID: https://orcid.org/0000-0003-4234-2124)
- Jeffrey Murray Burns (ORCID: https://orcid.org/0000-0001-7609-8954)
- Susan Alford
- H. K. Pandey (ORCID: https://orcid.org/0000-0001-7903-5844)
- Sheena K. Aurora (ORCID: https://orcid.org/0000-0002-4534-4937)
- Martí Jiménez‐Mausbach
Institutions
- University of Kansas (US)
- Novo Nordisk (Denmark) (DK)
- BioClinica (United States) (US)
- C2N Diagnostics (United States) (US)
- Novo Nordisk (United States) (US)
- Barrow Brain and Spine (US)
- The Navigator (Portugal) (PT)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_097183
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00